One composite stent patient, three acid-suppressing options: the NURS 6521 Week 6 gastrointestinal agent choice analysis compares them through mechanism, hepatic metabolism and an antiplatelet interaction. Searches like "nurs 6521 week 6 assignment example", "nurs6521 week 6 sample" and "nurs 6521 week 6 example" land here.
The NURS 6521 Week 6 example, in full
Acid Suppression for a 56-Year-Old Man on Dual Antiplatelet Therapy After a Coronary Stent, With a Prior Duodenal Ulcer and Fatty Liver Disease
Student Name
College of Nursing, Walden University
NURS 6521: Advanced Pharmacology
Instructor Name
Month Day, Year
Acid Suppression for a 56-Year-Old Man on Dual Antiplatelet Therapy After a Coronary Stent, With a Prior Duodenal Ulcer and Fatty Liver Disease
Case
Mr. K.J. is invented for this analysis. He is 56, a warehouse supervisor, and four months ago received a drug-eluting stent in his left anterior descending artery after an acute coronary syndrome. He takes aspirin 81 mg and clopidogrel 75 mg daily, with atorvastatin 80 mg and metoprolol succinate. Nine years ago he had a bleeding duodenal ulcer; Helicobacter pylori was found and eradicated, with a negative test afterward. He has metabolic dysfunction-associated fatty liver disease, with alanine aminotransferase about one and a half times the upper limit of normal, normal bilirubin and albumin, and no signs of cirrhosis. He has no current gastrointestinal symptoms. His cardiologist has asked primary care to decide on gastroprotection for the planned 12 months of dual antiplatelet therapy.
Constraint 1: Is Acid Suppression Needed?
Aspirin damages the gastroduodenal mucosa by inhibiting cyclooxygenase-1 and the prostaglandins that sustain mucosal defense, and both aspirin and clopidogrel impair platelet function, so any mucosal break bleeds more. His history of a bleeding ulcer is the strongest single predictor of another, even after the bacterium was eradicated (Lanas & Chan, 2017). Combining two antiplatelet agents raises bleeding risk further. Gastroprotection is therefore indicated. That settles the first question and turns the analysis to which agent.
The Classes Compared
Parietal cells secrete acid through the hydrogen-potassium ATPase, the proton pump, which is the final step shared by every stimulus to acid secretion. Proton pump inhibitors are prodrugs activated in the acidic canaliculus of the parietal cell, where they bind covalently and irreversibly to active pumps. Acid secretion recovers only as new pumps are made, so a once-daily dose suppresses acid through the day regardless of whether gastrin, histamine, or acetylcholine is driving secretion.
Histamine-2 receptor antagonists, such as famotidine, block one of those three stimuli, the histamine signal from enterochromaffin-like cells to the parietal cell. Gastrin and acetylcholine can still stimulate secretion, particularly after meals, and tolerance develops within weeks of continuous use. The result is less complete and less durable acid suppression. For preventing ulcer bleeding in patients on antiplatelet therapy, proton pump inhibitors are the more reliable class (Rosenthal & Burchum, 2021).
Antacids neutralize acid already secreted, act for an hour or two, and offer no meaningful protection against ulcer formation. They are excluded as a strategy. The comparison therefore favors a proton pump inhibitor on mechanism, which brings the analysis to the constraint that makes this case difficult.
Constraint 2: The Clopidogrel Interaction
Clopidogrel is itself a prodrug. About 85 percent of an oral dose is hydrolyzed by esterases to an inactive metabolite, and the remainder is converted in the liver, in two steps involving several cytochrome P450 enzymes, to the active thiol metabolite that irreversibly blocks the platelet P2Y12 receptor. CYP2C19 contributes to both steps. People who carry loss-of-function CYP2C19 alleles form less active metabolite and have higher rates of stent thrombosis and ischemic events on clopidogrel (Lee et al., 2022).
Several proton pump inhibitors are metabolized by CYP2C19 and inhibit it, and they differ in how strongly. Omeprazole and esomeprazole inhibit CYP2C19 enough to reduce clopidogrel's active metabolite, while pantoprazole inhibits it much less. In a randomized crossover study in healthy volunteers, omeprazole reduced exposure to clopidogrel's active metabolite and its inhibition of platelets, and separating the doses by 12 hours did not prevent the effect; pantoprazole produced a smaller reduction (Angiolillo et al., 2011). Separating doses fails because the interaction occurs at the enzyme, and both drugs have long enough effects on it to overlap regardless of timing.
How much this matters clinically has been debated. In the COGENT trial, adding omeprazole to clopidogrel and aspirin reduced upper gastrointestinal bleeding without a significant increase in cardiovascular events, although the trial ended early and its confidence intervals could not exclude a modest effect (Bhatt et al., 2010). The reasonable conclusion is that gastroprotection should not be withheld because of the interaction, and that when a proton pump inhibitor is chosen, one with less CYP2C19 inhibition removes a pharmacodynamic concern at no cost. This constraint shrinks the list to pantoprazole, or possibly another agent with weak CYP2C19 inhibition.
Constraint 3: Hepatic Function
Proton pump inhibitors are cleared almost entirely by hepatic metabolism, so liver disease could, in principle, raise exposure. The question is proportion. Mr. J.'s fatty liver disease causes a mild enzyme elevation with preserved synthetic function and no cirrhosis; his capacity to metabolize drugs is not meaningfully reduced. Pantoprazole requires no dose adjustment in mild or moderate hepatic impairment, and its wide margin of safety at standard doses means that even modestly increased exposure would not produce toxicity (Rosenthal & Burchum, 2021). Treating his liver enzymes as a contraindication to acid suppression would overstate the risk and leave him exposed to the more serious risk of recurrent bleeding. His liver disease does inform the plan in a different way: it is a reason to avoid unnecessary long-term medication, so the need for acid suppression is revisited when dual antiplatelet therapy ends.
Decision and Reassessment
The analysis selects pantoprazole 40 mg once daily, taken 30 minutes before breakfast, for the duration of dual antiplatelet therapy. Omeprazole and esomeprazole were rejected because of their stronger CYP2C19 inhibition, famotidine because it protects less reliably, and antacids because they do not prevent ulcers. At each visit, the plan reassesses gastrointestinal symptoms, signs of bleeding such as black stools or fatigue, and hemoglobin. When the cardiologist steps him down to a single antiplatelet agent, the continued need for pantoprazole is reconsidered, weighing his ulcer history against the long-term risks of acid suppression and his liver disease.
What Mr. J. Is Told
Mr. J. is told that his two heart medicines protect his stent but make bleeding from the stomach more likely, especially because of his old ulcer, and that pantoprazole lowers that risk by reducing stomach acid. He is told it was chosen over similar medicines because it interferes least with clopidogrel, so he should not switch to an over-the-counter acid reducer such as omeprazole on his own. He is asked to report black or tarry stools, vomiting blood or material that looks like coffee grounds, new stomach pain, or unusual tiredness or breathlessness, any of which could signal bleeding. He is reminded never to stop clopidogrel or aspirin without talking to his cardiologist, even if he has minor bleeding such as bruising or nosebleeds, because stopping early is the main cause of stent thrombosis. He is also asked to avoid over-the-counter anti-inflammatory pain relievers such as ibuprofen and naproxen, which add to the risk of ulcer bleeding, and to use acetaminophen at modest doses instead, mindful of his liver.
References
Angiolillo, D. J., Gibson, C. M., Cheng, S., Ollier, C., Nicolas, O., Bergougnan, L., Perrin, L., LaCreta, F. P., Hurbin, F., & Dubar, M. (2011). Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: Randomized, placebo-controlled, crossover comparison studies. Clinical Pharmacology & Therapeutics, 89(1), 65-74. https://doi.org/10.1038/clpt.2010.219
Bhatt, D. L., Cryer, B. L., Contant, C. F., Cohen, M., Lanas, A., Schnitzer, T. J., Shook, T. L., Lapuerta, P., Goldsmith, M. A., Laine, L., Scirica, B. M., Murphy, S. A., & Cannon, C. P. (2010). Clopidogrel with or without omeprazole in coronary artery disease. New England Journal of Medicine, 363(20), 1909-1917. https://doi.org/10.1056/NEJMoa1007964
Lanas, A., & Chan, F. K. L. (2017). Peptic ulcer disease. The Lancet, 390(10094), 613-624. https://doi.org/10.1016/S0140-6736(16)32404-7
Lee, C. R., Luzum, J. A., Sangkuhl, K., Gammal, R. S., Sabatine, M. S., Stein, C. M., Kisor, D. F., Limdi, N. A., Lee, Y. M., Scott, S. A., Hulot, J.-S., Roden, D. M., Gaedigk, A., Caudle, K. E., Klein, T. E., Johnson, J. A., & Shuldiner, A. R. (2022). Clinical Pharmacogenetics Implementation Consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clinical Pharmacology & Therapeutics, 112(5), 959-967. https://doi.org/10.1002/cpt.2526
Rosenthal, L. D., & Burchum, J. R. (2021). Lehne's pharmacotherapeutics for advanced practice nurses and physician assistants (2nd ed.). Elsevier.
What a finished NURS 6521 Week 6 gastrointestinal agent choice analysis looks like
Four pages under headings that follow the decision. The case section describes a man in his fifties taking two antiplatelet agents after a stent, with a past duodenal ulcer and liver enzymes mildly raised by fatty liver disease. The options section compares proton pump inhibitors, histamine-2 receptor antagonists and antacid therapy, explaining that the first class binds the proton pump irreversibly while the second blocks one of several signals driving acid secretion. The interaction section explains that clopidogrel is a prodrug activated by a hepatic enzyme some proton pump inhibitors inhibit, and that agents within the class differ in that effect. The hepatic section considers reduced clearance. A decision paragraph chooses a proton pump inhibitor with less enzyme inhibition and states what would be reassessed.
How a NURS 6521 Week 6 example is structured
The analysis is built like a decision with constraints, so the constraints appear before the options are ranked. Bleeding risk establishes that some acid suppression is needed, the interaction narrows which agents are acceptable, and hepatic function refines the choice within what remains. Each constraint gets its own section and ends on its consequence for the list of candidates, so the reader watches the options shrink. The comparison of classes is placed early and kept mechanistic, because the difference between blocking the pump and blocking one stimulus explains why one class protects more reliably. The interaction section is the longest, since it contains the reasoning weaker submissions skip. The conclusion names the chosen class and the rejected alternatives in two sentences, and a references page follows.
Three constraints, named up front
Ulcer history, dual antiplatelet therapy and fatty liver disease are listed together in the opening so every later section can refer back to them by name.
Pump versus receptor
The proton pump inhibitor acts at the final step of acid secretion; the receptor antagonist blocks only the histamine signal. That difference explains the gap in protection.
A prodrug that needs the liver
Clopidogrel must be converted to its active form by a hepatic enzyme. Inhibiting that enzyme could blunt its antiplatelet effect, which is why the choice within the class matters.
Clearance in an impaired liver
Mild impairment is weighed as a reason for caution rather than exclusion, and the section states what would change if the impairment were more advanced.
Choice and reassessment
The selected agent, the two rejected options, and the symptoms and findings that would prompt a second look, all set out without amounts.
Where marks go in NURS 6521 Week 6
Interaction reasoning is where this analysis earns or forfeits most of its credit. Submissions that recommend any proton pump inhibitor without noticing the antiplatelet agent miss the question the case was designed to ask. Mechanism rows reward precision about where each class acts, and describing both classes simply as reducing acid collapses the distinction the comparison depends on. Hepatic reasoning is marked on proportion: overstating mild impairment as a contraindication loses points as surely as ignoring it. A decision paragraph that names only the chosen agent, with no account of the alternatives, tends to land mid-range. Citations to current interaction evidence, not only to the textbook chapter, strengthen the evidence row considerably.
Get a NURS 6521 Week 6 example written to your instructions
Cases in this week vary by condition, from reflux to ulcer disease to inflammatory bowel disease, so send yours along with the rubric and prompt wording. Expect the analysis back in 24 to 48 hours, with the first custom one free. The stent patient on this page is fictional and exists only to show the reasoning a grader looks for.
NURS 6521 Week 6 questions, answered
Why does the example focus on an interaction instead of the stomach condition itself?
Because the stomach condition makes acid suppression obvious and the interaction makes the choice hard. A case that could be answered by naming any agent in the class would not show prescribing judgment. If your assigned case has no interacting drug, the analysis puts more weight on mechanism, duration of therapy and the risks of long-term acid suppression instead.
Does the analysis name specific drugs or only classes?
Both. Classes carry the comparison, and specific agents appear where the class is not uniform, which is the case for the interaction with clopidogrel. The analysis does not state amounts or schedules for any of them. Your submission may be expected to, and those details should come from the current prescribing references your course names.
Is the stent patient based on anyone?
No. The man in his fifties, his stent and his liver findings were invented to put three constraints on one decision. Any resemblance to an actual patient is incidental. If your prompt gives its own case, the analysis draws from those details only and does not add history the prompt left out.